SSD AF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SSD AF (SSD AF).
Silver sulfadiazine exerts bactericidal activity by releasing silver ions that bind to bacterial DNA and cell wall components, causing disruption of cellular respiration and DNA replication. It also inhibits bacterial cell wall synthesis via the sulfadiazine component.
| Metabolism | Silver sulfadiazine is not significantly metabolized; sulfadiazine component undergoes hepatic metabolism via acetylation and glucuronidation. |
| Excretion | Renal: ~10% as unchanged drug; biliary/fecal: ~90% as metabolites. |
| Half-life | Terminal elimination half-life is 6–8 hours; clinically, this supports twice-daily dosing in most patients. |
| Protein binding | Silver sulfadiazine is highly protein-bound (>95%), primarily to albumin. |
| Volume of Distribution | Not applicable for topical formulation; systemic absorption is minimal (<1%). |
| Bioavailability | Topical: negligible systemic absorption (<1%). |
| Onset of Action | Topical: within 24–48 hours for wound healing; oral: not applicable. |
| Duration of Action | Sustained antimicrobial effect for up to 24 hours after single application; reapplication is required for continued coverage. |
Apply a thin layer topically once or twice daily to affected area.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment; drug is minimally absorbed systemically. |
| Liver impairment | No dosage adjustment required for hepatic impairment; drug is minimally absorbed systemically. |
| Pediatric use | Apply a thin layer topically once or twice daily; same as adult dosing for ages 2 months and older. |
| Geriatric use | No specific dose adjustment; use same as adult dosing with caution for potential skin fragility. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SSD AF (SSD AF).
| Breastfeeding | Silver sulfadiazine is excreted into breast milk in low amounts; sulfonamides may cause kernicterus in nursing infants with G6PD deficiency or jaundice. M/P ratio: not established. Caution is advised; avoid use in breastfeeding if infant has G6PD deficiency or is premature. |
| Teratogenic Risk | SSD AF (silver sulfadiazine) is contraindicated in pregnancy, especially near term, due to risk of kernicterus from sulfonamide component. First trimester: potential for fetal harm based on animal data (cleft palate, skeletal anomalies). Second and third trimesters: sulfonamides cross placenta and may cause neonatal hyperbilirubinemia and kernicterus if used near delivery. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to silver sulfadiazine, sulfonamides, or any component of the formulation","Use in pregnant women at term or premature infants due to risk of kernicterus","Use in newborns during first 2 months of life"]
| Precautions | ["May cause hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency","Use with caution in patients with renal or hepatic impairment","Prolonged use may lead to bacterial resistance","May cause skin discoloration","Potential for sulfonamide-related adverse reactions"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of kernicterus in neonate if maternal use near term. Assess infant for hemolytic anemia, jaundice, and bilirubin levels if sulfonamide exposure. Monitor maternal renal and hepatic function due to potential sulfonamide toxicity. |
| Fertility Effects | No specific human data on fertility effects. Silver sulfadiazine may cause transient metalloprotein deposition in reproductive tissues; animal studies show no adverse effect on fertility at therapeutic doses. |